Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy

Click to increase image sizeClick to decrease image size

Disclosure statement

No potential conflict of interest was reported by the author(s). Dr. Przespolewski reports serving as clinical trial PI for Jazz Pharmaceuticals as well as funding for Investigator Initiated Study. Dr. Griffiths reports serving as clinical trial PI for Astex Pharmaceuticals, personal fees from Alexion Pharmaceuticals, clinical trial PI for Novartis, non-financial support, Investigator Initiated Study and Manuscript Support for Celgene/BMS, grants from Genentech, Inc., funding for Investigator Initiated Study from Celldex, Inc, independent assessor of protocol for Persimmune. Dr. Wang reports personal fees from Amgen, personal fees from Abbvie, personal fees from Astellas, personal fees from Jazz Pharmaceuticals, personal fees from Pfizer, personal fees from Daiichi Sankyo, personal fees from Arog/Dava Oncology, personal fees from PTC Therapeutics, personal fees from Macrogenics, personal fees from Stemline Therapeutics, personal fees from Kura Oncology, personal fees from Immunogen.